Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.770
-0.080 (-4.32%)
At close: Mar 9, 2026, 4:00 PM EDT
1.790
+0.020 (1.13%)
After-hours: Mar 9, 2026, 4:15 PM EDT
Lineage Cell Therapeutics Revenue
In the year 2025, Lineage Cell Therapeutics had annual revenue of $14.56M with 53.24% growth. Lineage Cell Therapeutics had revenue of $6.61M in the quarter ending December 31, 2025, with 130.40% growth.
Revenue (ttm)
$14.56M
Revenue Growth
+53.24%
P/S Ratio
30.97
Revenue / Employee
$189,039
Employees
77
Market Cap
438.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.56M | 5.06M | 53.24% |
| Dec 31, 2024 | 9.50M | 554.00K | 6.19% |
| Dec 31, 2023 | 8.95M | -5.76M | -39.16% |
| Dec 31, 2022 | 14.70M | 10.36M | 238.70% |
| Dec 31, 2021 | 4.34M | 2.52M | 137.73% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Autolus Therapeutics | 51.13M |
| Assembly Biosciences | 37.19M |
| Entrada Therapeutics | 25.42M |
| Upstream Bio | 2.80M |
| Shattuck Labs | 1.00M |
| 4D Molecular Therapeutics | 120.00K |
| vTv Therapeutics | 17.00K |
LCTX News
- 3 days ago - Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Business Wire
- 11 days ago - Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - Business Wire
- 2 months ago - Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience - Business Wire
- 2 months ago - Lineage Cell Therapeutics Issues Letter to Stockholders - Business Wire
- 4 months ago - Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy - Seeking Alpha
- 4 months ago - Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire